Entyvio denied by insurance? Appeal and win.
A denial for Entyvio is not the end of your treatment plan, it is simply the point where the documentation has to catch up to your medical history. Because vedolizumab is a gut-selective integrin biologic reserved for moderately to severely active ulcerative colitis or Crohn's disease, plans almost always deny it on step therapy, demanding proof that you failed, lost response to, or could not tolerate a TNF blocker such as infliximab or adalimumab, and they often dispute that your disease activity is severe enough to justify a biologic at all. What turns this denial around is a tight evidentiary record: the correct ICD-10 anchor (K51 for ulcerative colitis or K50 for Crohn's), a documented Mayo or CDAI activity score establishing moderate-to-severe disease, and a dated trial-and-failure or intolerance history for each prior agent the plan expected you to use, all tied to the FDA-labeled population your gastroenterologist is treating. When that chain is assembled correctly, the clinical case for coverage is no longer one the plan can credibly contest. We build that record for you and carry the appeal through every level it takes.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Moderate-to-severe ulcerative colitis and Crohn's disease.
Why Entyvio gets denied
- Step therapy: conventional therapy or a prior biologic not documented
- Prior-authorization criteria not documented
- Diagnosis or severity not evidenced
- Site-of-care restrictions for infusion
What a winning appeal includes
- Confirmed IBD diagnosis with severity and endoscopic findings
- Prior therapies and outcomes
- Gastroenterology support
- A letter of medical necessity
How we approach the appeal
Document the IBD diagnosis, severity, and prior-therapy failures, and address any site-of-care requirement for infusion.
Entyvio appeal letter template
Copy this Entyvio appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns Integrin-receptor biologic denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Entyvio denial I am appealing the denial of Entyvio (vedolizumab). I request that the denial be overturned and Entyvio approved. 1. The denial. [Insurer] denied Entyvio stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Entyvio is medically necessary for my condition. Document the IBD diagnosis, severity, and prior-therapy failures, and address any site-of-care requirement for infusion. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Entyvio within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Entyvio denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
Why was Entyvio denied?
Usually a step-therapy requirement or undocumented severity. GI documentation of prior failures and endoscopic findings is key.
Entyvio denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.